-
Je něco špatně v tomto záznamu ?
Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study)
C. Ciccarese, T. Büttner, L. Cerbone, I. Zampiva, FSM. Monteiro, U. Basso, M. Pichler, MG. Vitale, O. Fiala, G. Roviello, RM. Kopp, F. Carrozza, R. Pichler, F. Grillone, EP. Calabuig, A. Zeppellini, Z. Küronya, L. Galli, G. Facchini, K. Sunela,...
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, multicentrická studie
PubMed
39243397
DOI
10.1002/ijc.35141
Knihovny.cz E-zdroje
- MeSH
- dospělí MeSH
- imunoterapie metody MeSH
- inhibitory proteinkinas terapeutické užití MeSH
- karcinom z renálních buněk * patologie farmakoterapie imunologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory ledvin * patologie farmakoterapie imunologie mortalita MeSH
- prognóza MeSH
- protokoly antitumorózní kombinované chemoterapie terapeutické užití MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
Metastatic renal cell carcinoma (mRCC) carrying sarcomatoid features (sRCC) has aggressive biology and poor prognosis. First-line immunotherapy (IO)-based combinations have improved the outcome of clear cell RCC patients, including that of sRCC. Real-world data confirming the adequate first-line management of sRCC is largely lacking. We investigated the clinical features and the outcome of sRCC patients treated with IO-based combinations within the ARON-1 study population (NCT05287464). The primary objective was to define the incidence and baseline clinical characteristics of sRCC compared with non-sRCC patients. The secondary objective was to describe the outcome of sRCC patients based on type of first-line treatment (IO + IO vs. IO + tyrosin kinase inhibitor [TKI]). We identified 1362 mRCC patients with IMDC intermediate or poor risk, 226 sRCC and 1136 non-sRCC. These two subgroups did not differ in terms of baseline characteristics. The median overall survival (OS) was 26.8 months (95%CI 21.6-44.2) in sRCC and 35.3 months (95%CI 30.2-40.4) in non-sRCC patients (p = .013). The median progression-free survival (PFS) was longer in non-sRCC patients compared to sRCC (14.5 vs. 12.3 months, p = .064). In patients treated with first-line IO + TKI the median OS was 34.4 months compared to 26.4 months of those who received IO + IO (p = .729). The median PFS was 12.4 months with IO + TKI and 12.3 months with IO + IO (p = .606). In conclusion, we confirm that sRCC are aggressive tumors with poor prognosis. IO-based combinations improve survival outcomes of sRCC patients, regardless from the type of strategy (IO + IO versus IO + TKI) adopted.
Clinical Oncology Sociedad de oncología y hematología del Cesar Valledupar Colombia
Department of Medical and Surgical Sciences University of Bologna Bologna Italy
Department of Medical Oncology AUSL della Romagna Ospedale Civile degli Infermi Faenza Italy
Department of Medical Oncology Hospital Ramón y Cajal Madrid Spain
Department of Medical Oncology MD Anderson Cancer Center Madrid Madrid Spain
Department of Medical Oncology San Camillo Forlanini Hospital Rome Italy
Department of Urology Medical University of Innsbruck Innsbruck Austria
Department of Urology University Hospital Bonn Bonn Germany
Division of Medical Oncology A O U Consorziale Policlinico Di Bari Bari Italy
Division of Oncology Department of Internal Medicine Medical University of Graz Graz Austria
Medical Oncology Aprilia Hospital Latina Italy
Medical Oncology Department CHU Insular Materno Infantil Las Palmas de Gran Canaria Spain
Medical Oncology IRCCS Azienda Ospedaliero Universitaria di Bologna Bologna Italy
Medical Oncology National Cancer Centre Singapore Singapore Singapore
Medical Oncology Niguarda Cancer Center Grande Ospedale Metropolitano Niguarda Milan Italy
Medical Oncology Tawam Hospital Al Ain UAE
Medical Oncology Unit Department of Medicine and Surgery University of Parma Parma Italy
Medical Oncology Unit Fondazione Policlinico A Gemelli IRCCS Rome Italy
Oncology 3 Unit Department of Oncology Istituto Oncologico Veneto IOV IRCCS Padova Italy
Oncology and Hematology Department Hospital Sírio Libanê Brasília Brazil
Oncology Department Candiolo Cancer Institute IRCCS FPO Torino Italy
Oncology Operative Unit Santa Maria delle Grazie Hospital Pozzuoli Italy
Oncology Unit 2 University Hospital of Pisa Pisa Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25003280
- 003
- CZ-PrNML
- 005
- 20250206104223.0
- 007
- ta
- 008
- 250121s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/ijc.35141 $2 doi
- 035 __
- $a (PubMed)39243397
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Ciccarese, Chiara $u Medical Oncology Unit, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy $1 https://orcid.org/0000000232834339
- 245 10
- $a Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study) / $c C. Ciccarese, T. Büttner, L. Cerbone, I. Zampiva, FSM. Monteiro, U. Basso, M. Pichler, MG. Vitale, O. Fiala, G. Roviello, RM. Kopp, F. Carrozza, R. Pichler, F. Grillone, EP. Calabuig, A. Zeppellini, Z. Küronya, L. Galli, G. Facchini, K. Sunela, A. Mosca, J. Molina-Cerrillo, GP. Spinelli, J. Ansari, A. Scala, V. Mollica, E. Grande, S. Buti, R. Kanesvaran, R. Zakopoulou, A. Bamias, M. Rizzo, F. Massari, R. Iacovelli, M. Santoni
- 520 9_
- $a Metastatic renal cell carcinoma (mRCC) carrying sarcomatoid features (sRCC) has aggressive biology and poor prognosis. First-line immunotherapy (IO)-based combinations have improved the outcome of clear cell RCC patients, including that of sRCC. Real-world data confirming the adequate first-line management of sRCC is largely lacking. We investigated the clinical features and the outcome of sRCC patients treated with IO-based combinations within the ARON-1 study population (NCT05287464). The primary objective was to define the incidence and baseline clinical characteristics of sRCC compared with non-sRCC patients. The secondary objective was to describe the outcome of sRCC patients based on type of first-line treatment (IO + IO vs. IO + tyrosin kinase inhibitor [TKI]). We identified 1362 mRCC patients with IMDC intermediate or poor risk, 226 sRCC and 1136 non-sRCC. These two subgroups did not differ in terms of baseline characteristics. The median overall survival (OS) was 26.8 months (95%CI 21.6-44.2) in sRCC and 35.3 months (95%CI 30.2-40.4) in non-sRCC patients (p = .013). The median progression-free survival (PFS) was longer in non-sRCC patients compared to sRCC (14.5 vs. 12.3 months, p = .064). In patients treated with first-line IO + TKI the median OS was 34.4 months compared to 26.4 months of those who received IO + IO (p = .729). The median PFS was 12.4 months with IO + TKI and 12.3 months with IO + IO (p = .606). In conclusion, we confirm that sRCC are aggressive tumors with poor prognosis. IO-based combinations improve survival outcomes of sRCC patients, regardless from the type of strategy (IO + IO versus IO + TKI) adopted.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a karcinom z renálních buněk $x patologie $x farmakoterapie $x imunologie $7 D002292
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a nádory ledvin $x patologie $x farmakoterapie $x imunologie $x mortalita $7 D007680
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a protokoly antitumorózní kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a imunoterapie $x metody $7 D007167
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a inhibitory proteinkinas $x terapeutické užití $7 D047428
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a senioři nad 80 let $7 D000369
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Büttner, Thomas $u Department of Urology, University Hospital Bonn (UKB), Bonn, Germany
- 700 1_
- $a Cerbone, Linda $u Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy
- 700 1_
- $a Zampiva, Ilaria $u Section of Innovation Biomedicine-Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy
- 700 1_
- $a Monteiro, Fernando Sabino M $u Oncology and Hematology Department, Hospital Sírio Libanê, Brasília, Brazil
- 700 1_
- $a Basso, Umberto $u Oncology 3 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy
- 700 1_
- $a Pichler, Martin $u Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
- 700 1_
- $a Vitale, Maria Giuseppa $u Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy
- 700 1_
- $a Fiala, Ondrej $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen and Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Roviello, Giandomenico $u Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy
- 700 1_
- $a Kopp, Ray Manneh $u Clinical Oncology, Sociedad de oncología y hematología del Cesar, Valledupar, Colombia
- 700 1_
- $a Carrozza, Francesco $u Department of Medical Oncology, AUSL della Romagna, Ospedale Civile degli Infermi, Faenza, Italy
- 700 1_
- $a Pichler, Renate $u Department of Urology, Medical University of Innsbruck, Innsbruck, Austria $1 https://orcid.org/0000000152869048
- 700 1_
- $a Grillone, Francesco $u Oncologia, Oncologia PO Pugliese Ciaccio Azienda Ospedaliera Universitaria Renato Dulbecco, Catanzaro, Italy
- 700 1_
- $a Calabuig, Esther Pérez $u Medical Oncology Department, CHU Insular-Materno Infantil, Las Palmas de Gran Canaria, Spain
- 700 1_
- $a Zeppellini, Annalisa $u Medical Oncology, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy
- 700 1_
- $a Küronya, Zsófia $u Department of Genitourinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Budapest, Hungary
- 700 1_
- $a Galli, Luca $u Oncology Unit 2, University Hospital of Pisa, Pisa, Italy
- 700 1_
- $a Facchini, Gaetano $u Oncology Operative Unit, "Santa Maria delle Grazie" Hospital, Pozzuoli, Italy
- 700 1_
- $a Sunela, Kaisa $u Department of Oncology, Tampere University Hospital, Tampere Cancer Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
- 700 1_
- $a Mosca, Alessandra $u Oncology Department, Candiolo Cancer Institute, IRCCS-FPO, Torino, Italy
- 700 1_
- $a Molina-Cerrillo, Javier $u Department of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain $1 https://orcid.org/0000000346160598
- 700 1_
- $a Spinelli, Gian Paolo $u Medical Oncology, Aprilia Hospital, Latina, Italy
- 700 1_
- $a Ansari, Jawaher $u Medical Oncology, Tawam Hospital, Al Ain, UAE
- 700 1_
- $a Scala, Alessandro $u Medical Oncology Unit, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy
- 700 1_
- $a Mollica, Veronica $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
- 700 1_
- $a Grande, Enrique $u Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain
- 700 1_
- $a Buti, Sebastiano $u Medical Oncology Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy $1 https://orcid.org/0000000308760226
- 700 1_
- $a Kanesvaran, Ravindran $u Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
- 700 1_
- $a Zakopoulou, Roubini $u 2nd Propaedeutic Department of Internal Medicine, School of Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, Athens, Greece
- 700 1_
- $a Bamias, Aristotelis $u 2nd Propaedeutic Department of Internal Medicine, School of Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, Athens, Greece
- 700 1_
- $a Rizzo, Mimma $u Division of Medical Oncology, A.O.U. Consorziale Policlinico Di Bari, Bari, Italy
- 700 1_
- $a Massari, Francesco $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy $u Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy
- 700 1_
- $a Iacovelli, Roberto $u Medical Oncology Unit, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy $1 https://orcid.org/0000000217502117
- 700 1_
- $a Santoni, Matteo $u Oncology Unit, Macerata Hospital, Macerata, Italy
- 773 0_
- $w MED00002298 $t International journal of cancer $x 1097-0215 $g Roč. 155, č. 11 (2024), s. 2036-2046
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39243397 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206104218 $b ABA008
- 999 __
- $a ok $b bmc $g 2263184 $s 1239287
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 155 $c 11 $d 2036-2046 $e 20240907 $i 1097-0215 $m International journal of cancer $n Int J Cancer $x MED00002298
- LZP __
- $a Pubmed-20250121
